Schisandrin B Ameliorates Myocardial Ischemia/Reperfusion Injury Through Attenuation of Endoplasmic Reticulum Stress-Induced Apoptosis
- 219 Downloads
Schisandrin B (Sch B), an active composition isolated from the fruit of Schisandra chinensis, has been proved to possess antiinflammatory, antioxidant and anti-endoplasmic reticulum (ER) stress effects in many rodent tissues. However, the exact mechanism of cardioprotective effect of Sch B still needs more study. Here, we detected the effects of Sch B on myocardial ischemia/reperfusion (I/R) injury rats. I/R injury model in this study was established by left anterior descending coronary artery ligation for 40 min followed by 1 h of reperfusion. Male healthy rats were randomly divided into five groups: the sham, I/R, Sch B (20 mg/kg) + I/R, and Sch B (40 mg/kg) + I/R, Sch B (80 mg/kg) + I/R, with 10 rats in each group. We showed that Sch B treatment significantly protected against myocardial I/R injury, as demonstrated by the decrease in the percentage of infarct formation assessed by 2,3,5-triphenyl tetrazolium chloride (TTC) staining in representative heart tissue slices, comparing with the I/R control group. The levels of creatine kinase (CK), lactate dehydrogenase (LDH), malondialdehyde (MDA), and total superoxide dismutase (T-SOD) were tested. The ER stress-related proteins such as C/EBP homologous protein (CHOP), activating transcription factor 6 (ATF6), and (PKR)-like ER kinase (PERK) were further measured by western blot, and their messenger RNA levels were measured by real-time PCR. The apoptosis of heart tissue cells was also tested through the expressions of caspase-9, caspase-3, Bcl-2, and Bax proteins. Collectively, these results revealed that Sch B exerts protection role on myocardial I/R injury through decreasing oxidative reaction, suppressing ATF6 and PERK pathway, and attenuating ER stress-induced apoptosis.
KEY WORDSschisandrin B ischemia/reperfusion injury endoplasmic reticulum stress apoptosis
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Forouzanfar, M.H., A.E. Moran, A.D. Flaxman, G. Roth, G.A. Mensah, M. Ezzati, M. Naghavi, and C.J. Murray. 2012. Assessing the global burden of ischemic heart disease, part 2: analytic methods and estimates of the global epidemiology of ischemic heart disease in 2010. Global Heart 7: 331–342.CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Chi, H.J., Chen, M.L., Yang, X.C., Lin, X.M., Sun, H., Zhao, W.S., Qi, D., Cai, J., and Dong, J.L. 2016. Progress in therapies for myocardial ischemia reperfusion injury. Current drug targets 17.Google Scholar
- 7.Lu, S.F., Y. Huang, N. Wang, W.X. Shen, S.P. Fu, Q. Li, M.L. Yu, W.X. Liu, X. Chen, X.Y. Jing, and B.M. Zhu. 2016. Cardioprotective effect of electroacupuncture pretreatment on myocardial ischemia/reperfusion injury via antiapoptotic signaling. Evidence-based complementary and alternative medicine : eCAM 2016: 4609784.Google Scholar
- 17.Checker, R., R.S. Patwardhan, D. Sharma, J. Menon, M. Thoh, H.N. Bhilwade, T. Konishi, and S.K. Sandur. 2012. Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-kappaB. Free Radical Biology & Medicine 53: 1421–1430.CrossRefGoogle Scholar
- 18.Xu, Y., Liu, Z., Sun, J., Pan, Q.R., Sun, F.F., Yan, Z.Y., and Hu, X. 2011. Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo. Plos One 6.Google Scholar
- 19.Ko, K.M. 2004. Schisandrin B and other dibenzocyclooctadiene lignans. In: Herbal Medicines: Molecular Basis in Health & Diseases Management. Marcel Dekker New York Basel Hong Kong. 289–314.Google Scholar
- 25.Chiu, P.Y., H.Y. Leung, A.H. Siu, M.K. Poon, and K.M. Ko. 2007. Schisandrin B decreases the sensitivity of mitochondria to calcium ion-induced permeability transition and protects against ischemia-reperfusion injury in rat hearts. Acta Pharmacologica Sinica 28: 1559–1565.CrossRefPubMedGoogle Scholar